Breathtec Biomedical Inc. C.BTH Breathtec Biomedical Inc. (“Breathtec”) aims to propel development and commercialization of breath analysis screening technologies.
- Breathtec holds an option to acquire key University of Florida patent U.S. 8,237,118 entitled “Partial Ovoidal FAIMS Electrode.”
- FAIMS is a mass spectrometry technique that exploits differences in ion mobility at very high electric fields, to separate ions in the millisecond timescale after liquid chromatography separation and prior to introduction to a mass spectrometer.
FAIMS technology allows for miniaturization of breath testing devices and will enable development of non-invasive clinical screening.
- Eventual commercialization of FAIMS could revolutionize early detection of many deadly diseases.
- The Company is actively pursuing multiple, alternative research efforts into FAIMS technology.
Our Goal:
Develop a handheld breathalyzer
- Simplifies detection of diseases
- Real-time breath analysis
Non-invasive & Non-intrusive
- Collection anywhere, anytime
- Rapid results (minutes, not hours or days)
- Minimal handling/storage procedures
- Relatively simple analysis
Three Key Form Factors
Affordable
- Miniaturized electronics & sensors
- disposable consumables
Portable
- Phase one: desktop
- Phase two: handheld
Adaptable
- Internet connected
- Software updates
- Remote data capable